Form 8-K - Current report:
SEC Accession No. 0001564590-22-011680
Filing Date
2022-03-24
Accepted
2022-03-24 16:07:13
Documents
14
Period of Report
2022-03-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eldn-8k_20220324.htm   iXBRL 8-K 44700
2 EX-99.1 PRESS RELEASE eldn-ex99_8.htm EX-99 215008
3 GRAPHIC g2ucobzg5djw000001.jpg GRAPHIC 7626
  Complete submission text file 0001564590-22-011680.txt   399169

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eldn-20220324.xsd EX-101.SCH 5685
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eldn-20220324_lab.xml EX-101.LAB 19431
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eldn-20220324_pre.xml EX-101.PRE 11576
8 EXTRACTED XBRL INSTANCE DOCUMENT eldn-8k_20220324_htm.xml XML 3547
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36620 | Film No.: 22766542
SIC: 2834 Pharmaceutical Preparations